Nectar Lifesciences Limited — Investor Relations & Filings
Nectar Lifesciences Limited is a pharmaceutical organization specializing in the development and manufacturing of Active Pharmaceutical Ingredients (APIs) and finished dosage forms. The company maintains a significant focus on the cephalosporin segment, producing a wide range of oral and sterile products including Cefixime, Cefuroxime Axetil, and Ceftriaxone. Its operations encompass a fully integrated business model supported by large-scale manufacturing facilities that adhere to international regulatory standards such as USFDA and EUGMP. In addition to its core antibiotic portfolio, the company produces menthol and phytochemicals. Nectar Lifesciences serves a global clientele through contract manufacturing and development services, leveraging its research and development capabilities to provide high-quality therapeutic solutions across various international markets.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| General Updates | 2026-04-28 | English | |
| Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company | 2026-04-28 | English | |
| Disclosure under SEBI Takeover Regulations | 2026-04-09 | English | |
| General Updates | 2026-04-08 | English | |
| Certificate under SEBI (Depositories and Participants) Regulations, 2018 | 2026-04-06 | English | |
| Trading Window | 2026-03-25 | English |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 42202801 | General Updates | 2026-04-28 | English | ||
| 42206646 | Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company | 2026-04-28 | English | ||
| 42165209 | Disclosure under SEBI Takeover Regulations | 2026-04-09 | English | ||
| 42184123 | General Updates | 2026-04-08 | English | ||
| 42202572 | Certificate under SEBI (Depositories and Participants) Regulations, 2018 | 2026-04-06 | English | ||
| 42188801 | Trading Window | 2026-03-25 | English | ||
| 42198880 | Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company | 2026-03-24 | English | ||
| 42199270 | Shareholders meeting | 2026-03-13 | English | ||
| 42163979 | Agreements | 2026-03-12 | English | ||
| 42189395 | Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company | 2026-03-07 | English | ||
| 42194609 | Acquisition | 2026-03-06 | English | ||
| 42178464 | General Updates | 2026-03-03 | English | ||
| 42181671 | Acquisition | 2026-03-02 | English | ||
| 42182168 | Outcome of Board Meeting | 2026-03-02 | English | ||
| 42186377 | Shareholders meeting | 2026-03-01 | English | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
13260917 Canada Inc.
Biotech developing oral small molecules to restore muscle s…
|
MSCL | CA | Manufacturing |
|
1608557 Ontario Inc.
Biopharmaceutical company dedicated to R&D, discovery, and …
|
OTROQ | CA | Manufacturing |
|
3B BlackBio Dx Limited
Develops molecular diagnostic kits for oncology, infectious…
|
3BBLACKBIO | IN | Manufacturing |
|
3D Medicines Inc.
Commercial-stage biopharma specializing in next-generation …
|
1244 | HK | Manufacturing |
|
3SBio Inc.
Biopharmaceutical enterprise specializing in R&D, productio…
|
1530 | KY | Manufacturing |
|
4BASEBIO PLC
Manufactures GMP-grade synthetic DNA for next-generation th…
|
4BB | GB | Manufacturing |
|
4D Molecular Therapeutics, Inc.
Develops genetic medicines using AAV vectors for ophthalmol…
|
FDMT | US | Manufacturing |
|
4Front Ventures Corp.
Vertically integrated cannabis operator managing cultivatio…
|
FFNT | CA | Manufacturing |
|
4SC AG
Biopharmaceutical company with no products under developmen…
|
VSC | DE | Manufacturing |
|
60 DEGREES PHARMACEUTICALS, INC.
Develops and commercializes medicines for infectious diseas…
|
SXTP | US | Manufacturing |
Nectar Lifesciences Limited via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/59127/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=59127 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=59127 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=59127 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 59127}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Nectar Lifesciences Limited (id: 59127)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.